Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 6
Submit an article Journal homepage
190
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Olverembatinib in relapsed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: a study of 5 cases

Chunxiao Liua Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China;b Zhejiang Provincial Key Laboratory of Hematologic Malignancy, Zhejiang University, Hangzhou, PR China;c Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, PR China;d Zhejiang University Cancer Center, Hangzhou, PR ChinaView further author information
,
Xiang Zhanga Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China;b Zhejiang Provincial Key Laboratory of Hematologic Malignancy, Zhejiang University, Hangzhou, PR China;c Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, PR China;d Zhejiang University Cancer Center, Hangzhou, PR ChinaView further author information
,
Liping Maoa Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China;b Zhejiang Provincial Key Laboratory of Hematologic Malignancy, Zhejiang University, Hangzhou, PR China;c Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, PR China;d Zhejiang University Cancer Center, Hangzhou, PR ChinaView further author information
,
Jiejing Qiana Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China;b Zhejiang Provincial Key Laboratory of Hematologic Malignancy, Zhejiang University, Hangzhou, PR China;c Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, PR China;d Zhejiang University Cancer Center, Hangzhou, PR ChinaView further author information
,
Feng Xiaoa Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China;b Zhejiang Provincial Key Laboratory of Hematologic Malignancy, Zhejiang University, Hangzhou, PR China;c Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, PR China;d Zhejiang University Cancer Center, Hangzhou, PR ChinaView further author information
,
Xiujin Yea Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China;b Zhejiang Provincial Key Laboratory of Hematologic Malignancy, Zhejiang University, Hangzhou, PR China;c Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, PR China;d Zhejiang University Cancer Center, Hangzhou, PR ChinaView further author information
,
Juying Weia Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China;b Zhejiang Provincial Key Laboratory of Hematologic Malignancy, Zhejiang University, Hangzhou, PR China;c Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, PR China;d Zhejiang University Cancer Center, Hangzhou, PR ChinaView further author information
,
Xingnong Yea Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China;b Zhejiang Provincial Key Laboratory of Hematologic Malignancy, Zhejiang University, Hangzhou, PR China;c Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, PR China;d Zhejiang University Cancer Center, Hangzhou, PR ChinaView further author information
,
Jie Jina Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China;b Zhejiang Provincial Key Laboratory of Hematologic Malignancy, Zhejiang University, Hangzhou, PR China;c Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, PR China;d Zhejiang University Cancer Center, Hangzhou, PR ChinaCorrespondence[email protected]
View further author information
&
Wenjuan Yua Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China;b Zhejiang Provincial Key Laboratory of Hematologic Malignancy, Zhejiang University, Hangzhou, PR China;c Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, PR China;d Zhejiang University Cancer Center, Hangzhou, PR ChinaCorrespondence[email protected]
View further author information
 show all
Pages 1208-1211 | Received 29 Dec 2022, Accepted 25 Mar 2023, Published online: 17 Apr 2023

References

  • Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22(20):4075–4086.
  • Foa R, Chiaretti S. Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2022;386(25):2399–2411.
  • Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491–502.
  • Martinelli G, Boissel N, Chevallier P, et al. Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: final analysis of ALCANTARA study. Eur J Cancer. 2021;146:107–114.
  • Dhillon S. Olverembatinib: first approval. Drugs. 2022;82(4):469–475.
  • Ren X, Pan X, Zhang Z, et al. Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. J Med Chem. 2013;56(3):879–894.
  • Jabbour E, Koller PB, Oehler VG, et al. Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Blood 2022;140 (Supplement 1):200–202.
  • Weiyang L, Yuanfang L, Yongmei Z, et al. The first report of third-generation TKI olverembatinib in adult Ph/BCR-ABL1-positive acute lymphoblastic Leukemia with T315I mutation and relapsed disease. Blood 2022;140 (Supplement 1):3266–3267.
  • Qian J, Shi DY, Li ZR, et al. Updated results of pivotal phase 2 trials of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant BCR-ABL1 (T315I)-mutated chronic- and accelerated-phase chronic myeloid leukemia (CML-CP and CML-AP). Blood. 2021;138(Suppl. 1):3598–3598.
  • Pavlovsky C, Chan O, Talati C, et al. Ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. Future Oncol. 2019;15(3):257–269.
  • Abou Dalle I, Jabbour E, Short NJ, et al. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Treat Options Oncol. 2019;20(1):4.
  • Ravandi F, O'Brien SM, Cortes JE, et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015;121(23):4158–4164.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.